WO2000039118A1
(en)
*
|
1998-12-23 |
2000-07-06 |
Eli Lilly And Company |
Aromatic amides
|
DE10023485A1
(de)
*
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
|
DE10023486C1
(de)
*
|
2000-05-09 |
2002-03-14 |
Schering Ag |
Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
|
DE10023484A1
(de)
*
|
2000-05-09 |
2001-11-22 |
Schering Ag |
Anthranylamide und deren Verwendung als Arzneimittel
|
MXPA02012596A
(es)
|
2000-06-21 |
2003-04-10 |
Hoffmann La Roche |
Derivados de benzotiazol.
|
CA2430951A1
(en)
*
|
2000-12-07 |
2002-06-13 |
Cv Therapeutics, Inc. |
Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
*
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20030134836A1
(en)
|
2001-01-12 |
2003-07-17 |
Amgen Inc. |
Substituted arylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20020147198A1
(en)
*
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
PL414997A1
(pl)
|
2001-02-19 |
2016-02-29 |
Novartis Ag |
Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
JP2004528378A
(ja)
|
2001-05-08 |
2004-09-16 |
シエーリング アクチエンゲゼルシャフト |
N−オキシドアントラニルアミド誘導体と医薬製剤としての利用
|
DE50206476D1
(de)
*
|
2001-05-08 |
2006-05-24 |
Schering Ag |
Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
|
DE10123587B4
(de)
*
|
2001-05-08 |
2005-04-07 |
Schering Ag |
Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
|
IL158783A0
(en)
*
|
2001-05-08 |
2004-05-12 |
Schering Ag |
Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
|
DE10123573B4
(de)
*
|
2001-05-08 |
2005-06-02 |
Schering Ag |
N-Oxidanthranylamid-Derivate und deren Verwendung als Arzneimittel
|
DE60219617T2
(de)
|
2001-05-16 |
2008-01-03 |
Novartis Ag |
Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
|
EP1403255A4
(en)
*
|
2001-06-12 |
2005-04-06 |
Sumitomo Pharma |
INHIBITORS OF RHO KINASE
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
WO2003030902A1
(en)
|
2001-10-09 |
2003-04-17 |
Tularik Inc. |
Imidazole derivates as anti-inflammatory agents
|
GB0126902D0
(en)
*
|
2001-11-08 |
2002-01-02 |
Novartis Ag |
Organic compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
KR20120125398A
(ko)
|
2002-05-16 |
2012-11-14 |
노파르티스 아게 |
암에서 edg 수용체 결합제의 용도
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
DE10235690A1
(de)
*
|
2002-07-31 |
2004-02-19 |
Schering Ag |
VEGFR-2 und VEGFR-3 inhibitorische Anthranylamidpyridinamide
|
US7615565B2
(en)
*
|
2002-07-31 |
2009-11-10 |
Bayer Schering Pharma Aktiengesellschaft |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
|
US7338956B2
(en)
|
2002-08-07 |
2008-03-04 |
Sanofi-Aventis Deutschland Gmbh |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
|
EP1388341A1
(en)
*
|
2002-08-07 |
2004-02-11 |
Aventis Pharma Deutschland GmbH |
Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
|
EP1590338B1
(en)
*
|
2002-12-04 |
2009-08-26 |
Ore Pharmaceuticals Inc. |
Modulators of melanocortin receptor
|
TWI299664B
(en)
|
2003-01-06 |
2008-08-11 |
Osi Pharm Inc |
(2-carboxamido)(3-amino)thiophene compounds
|
US7696225B2
(en)
|
2003-01-06 |
2010-04-13 |
Osi Pharmaceuticals, Inc. |
(2-carboxamido)(3-Amino) thiophene compounds
|
US7087761B2
(en)
|
2003-01-07 |
2006-08-08 |
Hoffmann-La Roche Inc. |
Cyclization process for substituted benzothiazole derivatives
|
EP2308848A1
(en)
*
|
2003-02-03 |
2011-04-13 |
Janssen Pharmaceutica NV |
Quinoline-derived amide modulators of vanilloid VR1 receptor
|
ATE450533T1
(de)
*
|
2003-02-14 |
2009-12-15 |
Glaxo Group Ltd |
Carboxamidderivate
|
EP1602647B1
(en)
|
2003-03-07 |
2013-10-16 |
Santen Pharmaceutical Co., Ltd. |
Novel compound having 4-pyridylalkylthio group as substituent
|
CA2524048C
(en)
|
2003-05-19 |
2013-06-25 |
Irm Llc |
Immunosuppressant compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
US20050004133A1
(en)
*
|
2003-06-05 |
2005-01-06 |
Makings Lewis R. |
Modulators of VR1 receptor
|
DE10327719A1
(de)
*
|
2003-06-13 |
2005-01-20 |
Schering Ag |
VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
|
US7202260B2
(en)
|
2003-06-13 |
2007-04-10 |
Schering Ag |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
WO2005004864A1
(en)
*
|
2003-07-11 |
2005-01-20 |
Merck Patent Gmbh |
Benzimidazole derivatives as raf kinase inhibitors
|
GB0326601D0
(en)
*
|
2003-11-14 |
2003-12-17 |
Novartis Ag |
Organic compounds
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
NZ548949A
(en)
|
2004-02-17 |
2009-09-25 |
Santen Pharmaceutical Co Ltd |
Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
|
EP1568368A1
(en)
*
|
2004-02-26 |
2005-08-31 |
Schering Aktiengesellschaft |
Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
|
DE102004009238A1
(de)
*
|
2004-02-26 |
2005-09-08 |
Merck Patent Gmbh |
Arylamid-Derivate
|
WO2005085188A2
(en)
*
|
2004-03-02 |
2005-09-15 |
Compass Pharmaceuticals Llc |
Compounds and methods for anti-tumor therapy
|
US7427390B2
(en)
*
|
2004-03-10 |
2008-09-23 |
Schering Ag |
Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
|
DE102004011720B4
(de)
*
|
2004-03-10 |
2008-04-03 |
Bayer Schering Pharma Aktiengesellschaft |
Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie
|
PT1753760E
(pt)
|
2004-05-24 |
2008-02-12 |
Hoffmann La Roche |
'' - metoxi - 7 - morfolin - 4 - il - benzotiazol - 2 - il) - amida do ácido 4 - hidroxi - 4 - metil - piperidina - 1 - carboxílico''
|
DE102004039876A1
(de)
*
|
2004-06-23 |
2006-01-26 |
Lanxess Deutschland Gmbh |
Herstellung von fluorierten 1,3-Benzodioxanen
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
JP5156378B2
(ja)
|
2004-09-22 |
2013-03-06 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
MDM2とp53の間の相互作用の阻害剤
|
US7906533B2
(en)
*
|
2004-11-03 |
2011-03-15 |
Bayer Schering Pharma Ag |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
EP1657241A1
(en)
|
2004-11-03 |
2006-05-17 |
Schering Aktiengesellschaft |
Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
|
EP1655297A1
(en)
*
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
|
EP1655295A1
(en)
*
|
2004-11-03 |
2006-05-10 |
Schering Aktiengesellschaft |
Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
|
DE602005008095D1
(de)
|
2004-11-05 |
2008-08-21 |
Hoffmann La Roche |
Verfahren zur herstellung von isonikotinsäurederivaten
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
WO2006093253A1
(ja)
*
|
2005-03-03 |
2006-09-08 |
Santen Pharmaceutical Co., Ltd. |
キノリルアルキルチオ基を有する新規環式化合物
|
RU2412943C2
(ru)
|
2005-03-23 |
2011-02-27 |
Ф. Хоффманн-Ля Рош Аг |
ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
|
WO2006106914A1
(ja)
|
2005-03-31 |
2006-10-12 |
Santen Pharmaceutical Co., Ltd. |
ピリミジニルアルキルチオ基を有する新規環式化合物
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
ATE463495T1
(de)
|
2005-09-27 |
2010-04-15 |
Hoffmann La Roche |
Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
|
JP2009510073A
(ja)
|
2005-09-27 |
2009-03-12 |
ノバルティス アクチエンゲゼルシャフト |
カルボキシアミン化合物およびその使用方法
|
US8247556B2
(en)
*
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
ES2481671T3
(es)
|
2005-11-21 |
2014-07-31 |
Novartis Ag |
Inhibidores de mTOR en el tratamiento de tumores endocrinos
|
RU2008126228A
(ru)
*
|
2005-11-30 |
2010-01-10 |
Астеллас Фарма Инк. (Jp) |
2-аминобензамидное производное
|
JP5162574B2
(ja)
*
|
2006-03-22 |
2013-03-13 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Mdm2及びp53間の相互作用のインヒビターとしての環式アルキルアミン誘導体
|
JP5385125B2
(ja)
|
2006-03-22 |
2014-01-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
MDM2とp53の間の相互作用の阻害剤
|
RU2447891C2
(ru)
|
2006-04-05 |
2012-04-20 |
Новартис Аг |
Комбинации терапевтических средств, предназначенные для лечения рака
|
CA2649792A1
(en)
|
2006-05-09 |
2007-11-15 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
GB0612721D0
(en)
|
2006-06-27 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
WO2008077809A1
(en)
*
|
2006-12-22 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
Process for the manufacture of 7-oxa-bicyclo derivatives
|
CA2676163A1
(en)
|
2007-01-29 |
2008-08-07 |
Santen Pharmaceutical Co., Ltd. |
Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
|
AU2008216327A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of LBH589 with other therapeutic agents for treating cancer
|
EP1975166A1
(en)
*
|
2007-03-30 |
2008-10-01 |
Bayer Schering Pharma AG |
Synthesis of anthranilamides
|
US8853406B2
(en)
*
|
2007-08-06 |
2014-10-07 |
Janssen Pharmaceutica Nv |
Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53
|
WO2009118305A1
(en)
|
2008-03-26 |
2009-10-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
ES2445517T3
(es)
|
2008-08-27 |
2014-03-03 |
Leo Pharma A/S |
Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa
|
EP2344161B1
(en)
|
2008-10-16 |
2018-12-19 |
Celator Pharmaceuticals, Inc. |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
KR20170062554A
(ko)
|
2008-12-18 |
2017-06-07 |
노파르티스 아게 |
1-[4-[1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸]-2-에틸-벤질]-아제티딘-3-카르복실산의 헤미푸마레이트 염
|
WO2010080455A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
MX2011006610A
(es)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
|
US20110281917A1
(en)
|
2009-01-29 |
2011-11-17 |
Darrin Stuart |
Substituted Benzimidazoles for the Treatment of Astrocytomas
|
US8541442B2
(en)
|
2009-02-04 |
2013-09-24 |
Janssen Pharmaceutica N.V. |
Indole derivatives as anticancer agents
|
MY155570A
(en)
|
2009-06-26 |
2015-10-30 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
EA201200318A1
(ru)
|
2009-08-20 |
2012-09-28 |
Новартис Аг |
Гетероциклические оксимы
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
BR112012005400A2
(pt)
|
2009-09-10 |
2016-04-05 |
Irm Llc |
derivados do tipo éter de heteroarilas bicíclicas
|
CN102596951B
(zh)
|
2009-11-04 |
2015-04-15 |
诺华股份有限公司 |
用作mek抑制剂的杂环磺酰胺衍生物
|
JP2013512215A
(ja)
|
2009-11-25 |
2013-04-11 |
ノバルティス アーゲー |
二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体
|
GEP20135998B
(en)
|
2009-12-08 |
2013-12-25 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
CA2841142C
(en)
|
2010-06-23 |
2020-12-15 |
Ryan D. Morin |
Biomarkers for non-hodgkin lymphomas and uses thereof
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
KR102061353B1
(ko)
|
2010-09-10 |
2020-01-02 |
에피자임, 인코포레이티드 |
인간 ezh2의 억제제 및 이의 사용 방법
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
EP2681216B1
(en)
|
2011-02-28 |
2017-09-27 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
JO3438B1
(ar)
|
2011-04-13 |
2019-10-20 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
TW201733984A
(zh)
|
2011-04-13 |
2017-10-01 |
雅酶股份有限公司 |
經取代之苯化合物
|
EP2702052B1
(en)
|
2011-04-28 |
2017-10-18 |
Novartis AG |
17alpha-hydroxylase/c17,20-lyase inhibitors
|
CA2838029A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
MX339302B
(es)
|
2011-09-15 |
2016-05-19 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
EP2794592A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
EP2794591A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
JP2015503517A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物
|
AU2012355613A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
JP2015503516A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Bcl2と結合相手の相互作用を阻害するための化合物
|
CN102603729A
(zh)
*
|
2012-01-12 |
2012-07-25 |
贵州大学 |
N-(2-(取代苯并噻唑-2-氨基甲酰基)-取代苯基)吡啶甲酰胺类衍生物
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
WO2013138753A1
(en)
|
2012-03-16 |
2013-09-19 |
Fox Chase Chemical Diversity Center, Inc. |
Prodrugs of riluzole and their method of use
|
WO2013149581A1
(en)
|
2012-04-03 |
2013-10-10 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
LT3184523T
(lt)
|
2012-04-13 |
2020-02-10 |
Epizyme Inc |
N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
TWI588131B
(zh)
|
2012-10-15 |
2017-06-21 |
雅酶股份有限公司 |
經取代苯化合物
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
CN103130696B
(zh)
*
|
2013-03-21 |
2014-06-11 |
山东大学 |
邻氨基苯甲酰胺类化合物及其制备方法与应用
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
CN103405434A
(zh)
*
|
2013-08-22 |
2013-11-27 |
中国药科大学 |
Vegfr-2抑制剂及其用途
|
PL3057962T3
(pl)
|
2013-10-16 |
2024-01-29 |
Epizyme, Inc. |
Postać soli chlorowodorku do inhibicji ezh2
|
CN104163794A
(zh)
*
|
2013-10-17 |
2014-11-26 |
中国药科大学 |
2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
RU2695230C2
(ru)
|
2014-07-31 |
2019-07-22 |
Новартис Аг |
Сочетанная терапия
|
EP3697425A1
(en)
|
2017-10-18 |
2020-08-26 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
CA3166630A1
(en)
|
2020-01-03 |
2021-07-08 |
Berg Llc |
Polycyclic amides as ube2k modulators for treating cancer
|
WO2022222890A1
(en)
*
|
2021-04-19 |
2022-10-27 |
Shanghai Yao Yuan Biotechnology Co., Ltd. |
Benzothiazole and quinoline derivatives for use in treating kawasaki disease
|